The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of March 26, 2018.
Hi, I'm Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 26.
Number 5: A new brief from Avalere Health says that a variety of policy options are available to the United States to create the necessary conditions for biosimilar competition.
Number 4: Mylan and Biocon's Lantus biosimilar has received marketing authorization in the European Union and in Australia.
Number 3: Intravitreal anti-vascular endothelial growth factor treatments, including bevacizumab, are not associated with an increased risk of adverse events.
Number 2: In a symposium at the 23rd annual conference of the National Comprehensive Cancer Network, 3 clinicians presented on the use of biosimilars in oncology.
Number 1: FDA Commissioner, Dr Scott Gottlieb, said this week that the FDA is working on numerous new policies to encourage biosimilar development.
Finally, last week, our e-newsletter asked whether you think Oregon's new drug price transparency law will help to control costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.